Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Avalo Therapeutics announced the FDA has activated their IND application for AVTX-009, an anti-IL-1β monoclonal antibody, to treat hidradenitis suppurativa (HS). This green light allows Avalo to proceed with its Phase 2 LOTUS trial, aimed at evaluating the efficacy and safety of AVTX-009 in patients with moderate to severe HS. The company plans to enroll approximately 180 patients in this double-blind, placebo-controlled trial, with the first participant expected this year. Primary efficacy will be measured by the proportion of patients achieving a 75% reduction in HS symptoms by Week 16. Avalo's CEO, Dr. Garry Neil, expressed confidence in AVTX-009's potential as a best-in-class treatment due to its target specificity, half-life, and potency.
- FDA approval for IND application of AVTX-009.
- Commencement of Phase 2 LOTUS trial for AVTX-009.
- Potential for AVTX-009 to be best-in-class due to target specificity and potency.
- No concrete data on the efficacy or safety of AVTX-009 yet.
The initiation of a Phase 2 clinical trial for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), represents a significant move for Avalo Therapeutics. Hidradenitis Suppurativa (HS) is a chronic and painful skin condition with limited treatment options, so any advancements in this area are watched closely by both the medical community and investors. The efficacy and safety evaluation through a randomized, double-blind, placebo-controlled trial is a gold standard in clinical research, providing robust data on the drug's potential. The primary endpoint, HiSCR75, which measures a 75% reduction in inflammatory nodules and abscesses, is a critical measure of the drug's effectiveness.
For investors, this news is promising because it paves the way for potential market entry if the results are positive. However, it’s important to note that Phase 2 trials are primarily about safety and efficacy in a larger group than Phase 1, but they do not guarantee ultimate approval or commercial success. The fact that Avalo completed the IND application swiftly showcases their operational efficiency, which could translate into faster timelines for future milestones.
From a financial perspective, the activation of the IND for AVTX-009 and the commencement of the Phase 2 LOTUS trial is a positive development for Avalo Therapeutics. Moving into Phase 2 often results in increased investor confidence as it indicates progression in the drug development pipeline. However, investors should be cautious about the potential costs associated with conducting a large-scale trial on approximately 180 adults. Such trials are costly and resource-intensive, impacting the company’s financials in the short term.
Looking long-term, if AVTX-009 proves to be both safe and effective, it could lead to substantial revenue growth, given the limited treatment options for HS. Moreover, the potential for AVTX-009 to be 'best-in-class' suggests a significant market opportunity. Investors should keep an eye on upcoming trial readouts and the company’s funding strategies to support this and other ongoing trials.
- Following FDA review, Avalo’s IND application for AVTX-009 is active allowing Avalo to proceed with its Phase 2 trial (LOTUS) to evaluate the efficacy and safety of AVTX-009 in patients with hidradenitis suppurativa
WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year.
“This active IND is an important step for commencing the LOTUS trial in patients with hidradenitis suppurativa. I am proud of the Avalo team for achieving this milestone in just over three months from acquiring the product candidate in late March 2024,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “We believe that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing, and we look forward to getting the LOTUS Trial underway.”
The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens to evaluate the efficacy and safety of AVTX-009 in approximately 180 adults with moderate to severe HS. The primary efficacy endpoint is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response (HiSCR75) at Week 16. Subjects will be randomized (1:1:1) to receive either one of two doses of AVTX-009 or placebo.
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules, abscesses, and tunnels that form in areas of the body such as the armpits, groin, and buttocks, severely impacting the quality of life of affected individuals.1 HS is often underdiagnosed or misdiagnosed and therefore estimates of HS vary between 0.2
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in HS and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Avalo also has two additional product candidates which include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). For more information about Avalo, please visit www.avalotx.com.
Forward-Looking Statements
This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: timing of trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; integration of AVTX-009 into our operations; drug development costs; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
References
1Patel ZS et al. Curr Pain Headache Rep. 2017;21(12):49.
2Egeberg A, et al. JAMA Dermatol 2016;152:429–34
3Phan K, et al Biomed Dermatol 2020; 4: 2-6
4Jfri, A, et al. JAMA Dermatol. 2021;157(8):924-31
5Nguyen TV, et al. J Eur Acad Dermatol Venereol. 2021;35(1):50-61
For media and investor inquiries:
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Chris Brinzey
ICR Westwicke
Chris.brinzey@westwicke.com
339-970-2843
FAQ
What did Avalo Therapeutics announce regarding AVTX-009?
When is Avalo Therapeutics expected to enroll the first patient for the Phase 2 LOTUS trial?
What is the primary efficacy endpoint for the Phase 2 LOTUS trial?
What is the design of the Phase 2 LOTUS trial for AVTX-009?
How many patients will be enrolled in the Phase 2 LOTUS trial?
